CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights

Last Updated: Tuesday, November 18, 2025

A clinical review analyzing trial characteristics of 1,580 CAR-T trials registered on ClinicalTrials.gov as of April 2024. The review examines target specificity, treatment indication, and development stage of the trials. It also includes investigator surveys that identify barriers to development, future directions, and recommendations for CAR-T development.

Frontiers in Immunology

CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights

The Lancet

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma

Blood

Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Transplantation and Cellular Therapy

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome

Future Oncology

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Blood

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

CAR T-Cell Therapy Resource Center

CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights

Frontiers in Immunology

CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights

The Lancet

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma

Blood

Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Transplantation and Cellular Therapy

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome

Future Oncology

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Blood

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

Fast Facts #12: BCMA Targets